ReviewFrontiers in immunology2022

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.

Julia Hambach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.